Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853151 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
NCT00853151: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT00853151 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 131 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (118% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00853151, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
Study Summary
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
Primary Outcome
Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise \[D\&E\]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).
Interventions
- DRUG LY2428757
- DRUG TT223
- DRUG Placebo for LY2428757
- DRUG Placebo for TT223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00853151 record still lists
NCT00853151 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (118% higher).
The record links to 0 conditions, and to 4 interventions - of which LY2428757 is the first listed.
NCT00853151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00853151 about?
NCT00853151 is a clinical study titled "A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes". Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
What is the current status of trial NCT00853151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2009-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00853151?
The interventions under investigation include: LY2428757 (DRUG), TT223 (DRUG), Placebo for LY2428757 (DRUG), Placebo for TT223 (DRUG).
Who is sponsoring clinical trial NCT00853151?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00853151's enrollment target sits among peer trials
131 439th of 2000 higher than 1,562 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia